samedan logo
 
 
spacer
home > pmps > autumn 2008 > a revolution in aseptic filling
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

A Revolution in Aseptic Filling

The aseptic filling of injectable drugs has always been a challenge for the pharmaceutical industry. Contamination accidents, despite being rare, are still recorded among the 20 billion injections and infusions made every year in the world.

In a recent market study, six per cent of hospital professionals in Europe and the US reported that they have already faced at least one case of contaminated vials. In recent years, the authorities have taken a radical turn to strongly support the most advanced aseptic filling technologies, such as the use of isolators, whereas the use of classical processes in an Iso 5/Grade A cleanroom are more and more questioned, as the risks caused by proximity of operators to the open containers becomes evident...


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Benoоt Verjans has a PhD degree in Biochemistry and a MBA from the University of Brussels. He has developed a post-doctoral programme at the University of Cambridge (UK). He worked at UCB Pharma in International Marketing, at McKinsey and Co as a consultant, in the pharma sector (marketing, supply chain and licensing projects), and as CEO of 4AZA Bioscience, a start-up from the University of Leuven developing new immuno-modulating drugs. He is currently Commercial Director of Aseptic Technologies, responsible for developing the sales of closed vial technology worldwide. He is on the Editorial Board of Pharmaceutical Technology Europe and a member of ISPE.
spacer
Benoоt Verjans
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

KKR Invests in Biosynth Carbosynth to Accelerate Growth and Help Build Global Life Sciences Tools Platform

London and Staad, 1 November 2021 KKR, a leading global investment firm, and Biosynth Carbosynth, a leading life sciences reagents and custom synthesis and manufacturing services company, announce today that KKR has agreed to acquire Biosynth Carbosynth from Armira and CEO Dr. Urs Spitz. Dr. Spitz and senior managers of the company will retain a significant ownership stake and will continue to lead the company as it embarks on its next chapter of growth. Financial details of the transaction, which is subject to customary regulatory approvals, were not disclosed.
More info >>

White Papers

Using Device Strategy to Drive R&D Productivity

Phillips-Medisize


More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement